搜索范围
N0761
应用筛选条件
关键词:'N0761'
显示 1-30 #N/A 209 条结果 关于 "N0761" 范围 论文
Pieter-Jan De Kam et al.
Platelets, 25(7), 480-487 (2013-11-12)
Laropiprant is an antagonist of the prostaglandin PGD2 receptor DP1. Laropiprant has a weak affinity for the thromboxane A2 receptor TP. Two double-blinded, randomized, placebo-controlled, crossover studies evaluated the effects of multiple-dose laropiprant at steady state on the antiplatelet effects
D L Cooper et al.
European review for medical and pharmacological sciences, 19(20), 3977-3988 (2015-11-05)
Niacin, activating G-protein coupled receptor (GPR) 109A, stimulates release of vasodilatory prostaglandins (PGs) such as PGE2 which can elicit niacin-associated flushing side effects. Poly-lactic-co-glycolic acid (PLGA) and poly-lactic acid (PLA) are used in nanoparticle (NP) drug delivery to reduce adverse
U Julius et al.
Atherosclerosis. Supplements, 14(1), 7-13 (2013-01-30)
Nicotinic acid has complex effects on lipoprotein metabolism; it increases HDL cholesterol, decreases triglycerides and LDL cholesterol. It also reduces lipoprotein(a) levels by about 25% and exerts certain effects that may be antiatherogenic. Studies performed in the pre-statin era demonstrated
The peeling dermatitis with a peculiar demarcation.
Tai-Heng Chen et al.
The American journal of the medical sciences, 346(5), 421-421 (2012-11-02)
Tobias Kroon et al.
Journal of lipid research, 56(9), 1679-1690 (2015-07-15)
Acute nicotinic acid (NiAc) administration results in rapid reduction of plasma FFA concentrations. However, sustained NiAc exposure is associated with tolerance development resulting in return of FFA to pretreatment levels. The aim of this study was to determine whether a
Baiba K Gillard et al.
Arteriosclerosis, thrombosis, and vascular biology, 33(7), 1714-1721 (2013-05-04)
HIV patients on antiretroviral therapy (HIV/ART) exhibit a unique atherogenic dyslipidemic profile with hypertriglyceridemia (HTG) and low plasma concentrations of high-density lipoprotein (HDL) cholesterol. In the Heart Positive Study of HIV/ART patients, a hypolipidemic therapy of fenofibrate, niacin, diet, and
Takeki Uehara et al.
Molecular nutrition & food research, 54(2), 218-227 (2009-12-31)
Biotechnology advances have provided novel methods for the risk assessment of chemicals. The application of microarray technologies to toxicology, known as toxicogenomics, is becoming an accepted approach for identifying chemicals with potential safety problems. Gene expression profiling is expected to
Robert Ringseis et al.
The Journal of nutrition, 143(2), 125-131 (2012-12-21)
In the present study, we tested the hypothesis that niacin increases the oxidative capacity of muscle by increasing the oxidative type I muscle fiber content. Twenty-four obese Zucker rats were assigned to 2 groups of 12 rats that were fed
Kimberly A Gudzune et al.
Annals of internal medicine, 160(7), 468-476 (2014-02-12)
Some patients do not tolerate or respond to high-intensity statin monotherapy. Lower-intensity statin combined with nonstatin medication may be an alternative, but the benefits and risks compared with those of higher-intensity statin monotherapy are unclear. To compare the clinical benefits
Umi Fahmida et al.
Food and nutrition bulletin, 35(4 Suppl), S174-S179 (2015-02-03)
Affordable, locally contextual complementary feeding recommendations (CFRs) that take into account cultural diversity and differences in food availability will be more likely to result in long-term improvements in complementary feeding practices than general recommendations. More objective approaches, such as linear
Tawfik Gharbaoui et al.
Bioorganic & medicinal chemistry letters, 17(17), 4914-4919 (2007-06-26)
A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series
Angela Pirillo et al.
Cardiology, 124(2), 116-125 (2013-02-23)
Although the inverse relationship between plasma levels of high-density lipoprotein (HDL) and cardiovascular disease has been largely demonstrated, many observations have suggested that the assessment of HDL functionality might be more informative than a simple measurement of HDL-cholesterol plasma levels.
Kelly W Jones
JAAPA : official journal of the American Academy of Physician Assistants, 26(7), 9-10 (2013-08-08)
Niacin has been used for years to treat hypercholesterolemia, but may not be as beneficial as thought for patients at high risk of cardiovascular disease. Until further research is done, niacin should be used only in patients who do not
Rachael Hartman et al.
Dermatology online journal, 17(10), 11-11 (2011-10-28)
We report the case of a 63-year-old obese man with a rapid-onset of widespread acanthosis nigricans (AN) in the setting of having recently initiated treatment with niacin for dyslipidemia. Although obesity and insulin-resistance are risk factors for AN, AN associated
Julia C Creider et al.
Nature reviews. Endocrinology, 8(9), 517-528 (2012-02-22)
Niacin, or water-soluble vitamin B(3), when given at pharmacologic doses, is a powerful lipid-altering agent. This drug, which lowers the levels of atherogenic, apolipoprotein-B-containing lipoproteins, is one of few medications that can raise the levels of atheroprotective HDL cholesterol. Niacin
Hua Huang et al.
PloS one, 9(12), e114643-e114643 (2014-12-19)
Niacin reduces vascular oxidative stress and down regulates inducible nitric oxide synthase, an enzyme mediating proatherosclerotic effects in part by increasing oxidative stress. Here, we evaluate whether Niacin reverses the redox sensitive migratory arrest of macrophages in response to oxidised(ox)
Amanda Rennick et al.
Pharmacotherapy, 33(6), 683-690 (2013-03-26)
Phosphate binders have traditionally been used to treat hyperphosphatemia, a common complication in patients with end stage renal disease (ESRD). New evidence suggests that nicotinic acid and its metabolites may effectively decrease phosphorus absorption in the gastrointestinal tract, thereby reducing
Niacin for reduction of cardiovascular risk.
Inge A M van den Oever et al.
The New England journal of medicine, 371(20), 1942-1942 (2014-11-13)
Ibragim Gaidarov et al.
Cellular signalling, 25(10), 2003-2016 (2013-06-19)
Until recently, the anti-atherosclerotic effects of niacin were attributed primarily to its lipid modification properties mediated by adipocyte G-protein coupled receptor GPR109A, though recent studies have raised significant doubts about this mechanism. In fact, in rodents it has recently been
James B Kirkland
Mutation research, 733(1-2), 14-20 (2011-12-06)
Through its involvement in over 400 NAD(P)-dependent reactions, niacin status has the potential to influence every area of metabolism. Niacin deficiency has been linked to genomic instability largely through impaired function of the poly ADP-ribose polymerase (PARP) family of enzymes.
Matilda Florentin et al.
Current vascular pharmacology, 9(4), 385-400 (2011-02-15)
Treatment with statins has significantly reduced cardiovascular morbidity and mortality, an effect attributed to both the low-density lipoprotein cholesterol (LDL-C) lowering capacity and the pleiotropic actions of these drugs. However, residual risk remains even after intense LDL-C lowering. Therefore, additional
James M Backes et al.
Postgraduate medicine, 123(2), 70-83 (2011-04-09)
Niacin is a water-soluble B vitamin (B3) known to have favorable effects on multiple lipid parameters, including raising high-density lipoprotein cholesterol (HDL-C) levels and lowering triglycerides (TGs), lipoprotein(a), and low-density lipoprotein cholesterol (LDL-C). Although LDL-C remains the primary target of
Caroline M Perry
Drugs, 69(12), 1665-1679 (2009-08-15)
Extended-release (ER) niacin (nicotinic acid)/laropiprant is a once-daily fixed-dose combination tablet that has been evaluated (with or without an HMG-CoA reductase inhibitor [statin]) in the treatment of adults with dyslipidaemia or primary hypercholesterolaemia. Niacin (vitamin B3) is a lipid-modifying drug
Vladimir Tolstikov et al.
PloS one, 9(12), e114019-e114019 (2014-12-09)
Nicotinamide phosphoribosyltransferase (NAMPT) plays an important role in cellular bioenergetics. It is responsible for converting nicotinamide to nicotinamide adenine dinucleotide, an essential molecule in cellular metabolism. NAMPT has been extensively studied over the past decade due to its role as
Chiara Zucal et al.
BMC cancer, 15, 855-855 (2015-11-07)
Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD(+) biosynthesis from nicotinamide, is one of the major factors regulating cancer cells metabolism and is considered a promising target for treating cancer. The prototypical NAMPT inhibitor FK866 effectively lowers NAD(+) levels in
Niacin--a case study for the role of event-driven versus surrogate endpoint trials.
Michael J Blaha et al.
Heart (British Cardiac Society), 99(22), 1631-1632 (2013-09-18)
Hong C Shen et al.
Bioorganic & medicinal chemistry letters, 17(24), 6723-6728 (2007-11-22)
A urea class of high affinity niacin receptor agonists was discovered. Compound 1a displayed good PK, better in vivo efficacy in reducing FFA in mouse than niacin, and no vasodilation in a mouse model. Compound 1q demonstrated equal affinity to
John A Farmer
Current atherosclerosis reports, 11(2), 87-92 (2009-02-21)
Dyslipidemia is central to the process of atherosclerosis. Modification of the lipid profile by diet, exercise, or pharmacologic therapy has been demonstrated to reduce the risk from atherosclerosis in clinical studies in primary and secondary prevention. Nicotinic acid has been
Kaori Taguchi et al.
Journal of chromatography. A, 1362, 270-277 (2014-09-10)
Chromatography techniques usually use a single state in the mobile phase, such as liquid, gas, or supercritical fluid. Chromatographers manage one of these techniques for their purpose but are sometimes required to use multiple methods, or even worse, multiple techniques
Xiao-lin Wang et al.
European journal of drug metabolism and pharmacokinetics, 39(4), 321-326 (2013-12-19)
The gender differences in pharmacokinetics of a combination tablet of niacin extended-release/simvastatin were evaluated in healthy Chinese volunteers. Thirty-six healthy male and female volunteers were enrolled in the study receiving a single oral dose of niacin extended-release/simvastatin 1,000/20 mg. The results
1/7